Derivation Web

claim_36ac608c40354f32

# Hypothesis-Generating Brief: SGLT2 inhibitor — full paper
## Abstract

Evidence-honesty note: 10/12 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

This paper synthesizes evidence on SGLT2 inhibitor across 12 included source papers and 692 high-con…

source_14aa497b978a48e9

# Hypothesis-Generating Brief: SGLT2 inhibitor — full paper
## Abstract

Evidence-honesty note: 10/12 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

This paper synthesizes evidence on SGLT2 inhibitor across 12 included source papers and 692 high-con…

source_da69fef9d2bd4eca

{"publication_id": "89c570cf-7f20-49de-a349-6ab8241f2855", "traces": [{"candidate_sources": [{"directness": "primary", "doi": "10.1038/s41591-021-01536-x", "effect": "not extracted", "endpoint": "not extracted", "population": "not extracted", "source_id": "source_1", "study": "The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial", "sup…

source_8cc23e02282d4146

{"content_hash": "sha256:3f33941f6a4172a7295dfb062d08c7e3758574c54db5290f8f89833f67d3102e", "edges": [{"from": "89c570cf-7f20-49de-a349-6ab8241f2855", "to": "claim_1", "type": "contains_claim"}, {"from": "89c570cf-7f20-49de-a349-6ab8241f2855", "to": "claim_2", "type": "contains_claim"}, {"from": "89c570cf-7f20-49de-a349-6ab8241f2855", "to": "claim_3", "type": "contains_claim"}, {"from": "89c570cf-…

source_be4b3a414a2b42e0

{"contradictions": ["Positive study-level signals are summarized in the safety outcome class; null signals are not the dominant direction in any outcome class; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the contextual adjacent evidence, cardiometabolic, safety and comorbidity, and longevity outcome classes. The paper there…

source_d9d9208b54c540ba

study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Network meta-analysis on the efficacy and safety of finerenone versus SGLT2 inh…

source_2966d3a81e424f56

{"method_note": "Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.", "publication_id": "89c570cf-7f20-49de-a349-6ab8241f2855", "sources": [{"directness": "primary", "doi": "10.1038/s41591-021-01536-x", "risk_of_bias": "not appraised in public sidecar", "study": "The SGLT2 inhibitor dapagliflozin in heart failure with preser…

source_a25c2b74ef5242a4

{"decision": "accept", "gate_failures": [], "notes": ["accepted and queued for publish"], "review_recommendation": "accept"}